(ANIK) Anika Therapeutics - Ratings and Ratios

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a joint preservation company specializing in early intervention orthopedic care. The firm develops and commercializes solutions for osteoarthritis (OA) pain management, regenerative therapies, sports medicine, and arthrosurface joint solutions. Its product portfolio is built on a hyaluronic acid (HA) technology platform, offering injectable viscosupplements like Monovisc and Orthovisc for OA pain relief, as well as Cingal, a single-injection product providing both short- and long-term pain relief. The company also markets joint preservation and restoration solutions, including Hyalofast and Tactoset for orthopedic regeneration, sports medicine products for ligament and tendon repair, and joint replacement implants for upper and lower extremity conditions.

Beyond orthopedics, Anika offers non-orthopedic HA-based products such as Hyvisc for veterinary use, Hyalobarrier as an anti-adhesion barrier for surgeries, and Hyalomatrix for wound healing. The company, founded in 1983 and headquartered in Bedford, Massachusetts, operates in the U.S., Europe, and internationally. Web URL: https://www.anika.com

Ticker Symbol: ANIK
Exchange: NASDAQ
Type: common stock
Country Origin: United States
GICS Sub Industry: Biotechnology

Average Volume 20d: 62992
Last Price: 17.45
SMA 20: 17.64
SMA 50: 16.83
SMA 200: 22.16
ATR: 0.57

Market Cap: 254.69M USD
P/E: 0.00
P/E Forward: 37.59
P/B: 1.44
P/S: 1.55
RoE: -54.22

3-Month Forecast: Based on and , Anika Therapeutics (NASDAQ: ANIK) is expected to face mixed market conditions. The stock price, currently below its 20-day SMA (17.64) but above its 50-day SMA (16.83), suggests short-term volatility. The low ATR (0.57) indicates limited price movement. On the fundamental side, the negative P/E ratio (-54.22 RoE) signals profitability challenges, while the forward P/E (37.59) reflects market expectations for growth. The moderate P/S ratio (1.55) and P/B ratio (1.44) suggest the stock is fairly valued relative to its assets and sales. Overall, the stock may experience downward pressure due to profitability concerns but could stabilize if the company demonstrates progress in revenue growth and margin improvement.